Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effects of AD098, AD153 and AD639 on obstructive sleep apnoea (OSA) severity in men and women with moderate-to-severe OSA

Next Previous
X
Search
Trial Profile

The effects of AD098, AD153 and AD639 on obstructive sleep apnoea (OSA) severity in men and women with moderate-to-severe OSA

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AD 098 (Primary) ; AD 153 (Primary) ; AD 639 (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Sponsors Apnimed

    • Most Recent Events

    • 20 May 2020 Primary endpoint has not been met. (Sleep apnoea severity using the apnoea/hypopnoea index from the overnight polysomnogram)
    • 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
    • 30 Sep 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top